ReviewCritical reviews in oncogenesis2015
Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?
Review in Critical reviews in oncogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 88 citations in OpenAlex.
- Ewing's sarcoma family of tumors in adolescents in Beijing 2010-2019: a multicenter retrospective cohort study.Translational pediatrics · 2025Article
- Regulation of Metastasis in Ewing Sarcoma.Cancers · 2022Review
- Comparative characteristics of small cell lung cancer and Ewing's sarcoma: a narrative review.Translational lung cancer research · 2022Review
- Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income country.Ecancermedicalscience · 2022Article
- Ewing's sarcoma of the hip: A case report with no evidence of tumor recurrence and literature review.Bone reports · 2021Article
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development.Life sciences · 2021Article
- Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma.PLoS computational biology · 2021Article
- Article
- NELL2-cdc42 signaling regulates BAF complexes and Ewing sarcoma cell growth.Cell reports · 2021Article
- EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.Molecular cancer research : MCR · 2021Article
- Article
- Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.Cancer research · 2021Article
- Exploiting Replication Stress as a Novel Therapeutic Intervention.Molecular cancer research : MCR · 2021Review
- Inactivation of ICAM1 inhibits metastasis and improves the prognosis of Ewing's sarcoma.Journal of cancer research and clinical oncology · 2021Article
- Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma.Cancers · 2021Article
- YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells.Oncogenesis · 2021Article
- Human Serum Enhances Biomimicry of Engineered Tissue Models of Bone and Cancer.Frontiers in bioengineering and biotechnology · 2021Article
- Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment.Frontiers in cell and developmental biology · 2021Review
- Advances in the Management of Pediatric Sarcomas.Current oncology reports · 2020Review
- GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth.Cell reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Ewing sarcoma (ES) is a highly aggressive bone and soft-tissue tumor with peak incidence among adolescents and young adults. Despite advances in local control and systemic chemotherapy, metastatic relapse after an initial clinical remission remains a significant clinical problem. In addition, metastasis at the time of presentation or at relapse continues to be the leading cause of death for patients diagnosed with ES. Since the discovery of the pathognomonic EWS-FLI1 fusion gene more than 20 years ago, much about the molecular and cellular biology of ES pathogenesis has been learned. In addition, more recent exploitation of advances in stem cell and developmental biology has provided key insights into the cellular origins of ES and the role of epigenetic deregulation in tumor initiation and maintenance. Nevertheless, the mechanisms that drive tumor relapse and metastasis remain largely unknown. These gaps in our knowledge continue to hamper the development of novel therapeutic strategies that may improve outcomes for patients with relapsed and metastatic disease. In this article we review the current status of ES biology research, highlighting areas of investigation that we consider to have the greatest potential to yield findings that will translate into clinically significant advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.